BRPI0607043A2 - lacosamida para terapia de adição - Google Patents

lacosamida para terapia de adição

Info

Publication number
BRPI0607043A2
BRPI0607043A2 BRPI0607043-4A BRPI0607043A BRPI0607043A2 BR PI0607043 A2 BRPI0607043 A2 BR PI0607043A2 BR PI0607043 A BRPI0607043 A BR PI0607043A BR PI0607043 A2 BRPI0607043 A2 BR PI0607043A2
Authority
BR
Brazil
Prior art keywords
lacosamide
addiction therapy
therapy
addiction
addition therapy
Prior art date
Application number
BRPI0607043-4A
Other languages
English (en)
Inventor
Thomas Stoehr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BRPI0607043A2 publication Critical patent/BRPI0607043A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LACOSAMIDA PARA TERAPIA DE ADIçãO. A presente invenção refere-se ao uso de uma classe de compostos peptídicos para a prevenção, alívio e/ou tratamento de uma doença que seja tratada com antipsicóticos, em particular psicose, mais particularmente esquizofrenia,em uma terapia de adição a pelo menos um antipsicótico.
BRPI0607043-4A 2005-01-28 2006-01-27 lacosamida para terapia de adição BRPI0607043A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia
PCT/EP2006/000722 WO2006079547A2 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
BRPI0607043A2 true BRPI0607043A2 (pt) 2009-08-04

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607043-4A BRPI0607043A2 (pt) 2005-01-28 2006-01-27 lacosamida para terapia de adição

Country Status (12)

Country Link
EP (1) EP1841417A2 (pt)
JP (1) JP2008528532A (pt)
KR (1) KR20070096058A (pt)
AR (1) AR057643A1 (pt)
AU (1) AU2006208630B2 (pt)
BR (1) BRPI0607043A2 (pt)
CA (1) CA2595330A1 (pt)
EA (1) EA015566B1 (pt)
IL (1) IL183973A0 (pt)
MX (1) MX2007009070A (pt)
NO (1) NO20074361L (pt)
WO (1) WO2006079547A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2214657A1 (en) 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions
WO2010077916A1 (en) * 2008-12-16 2010-07-08 Eurand, Inc. Compositions comprising melperone
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.

Also Published As

Publication number Publication date
JP2008528532A (ja) 2008-07-31
CA2595330A1 (en) 2006-08-03
AR057643A1 (es) 2007-12-12
KR20070096058A (ko) 2007-10-01
EA200701594A1 (ru) 2008-02-28
EA015566B1 (ru) 2011-10-31
MX2007009070A (es) 2007-09-12
AU2006208630A1 (en) 2006-08-03
WO2006079547A2 (en) 2006-08-03
AU2006208630B2 (en) 2011-09-29
IL183973A0 (en) 2008-12-29
WO2006079547A3 (en) 2006-09-21
EP1841417A2 (en) 2007-10-10
NO20074361L (no) 2007-10-26

Similar Documents

Publication Publication Date Title
BRPI0607043A2 (pt) lacosamida para terapia de adição
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
MX2009011127A (es) Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
TNSN08400A1 (en) Organic compounds and their uses
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
BRPI0508758A (pt) processo para a preparação de cloridrato de oxicodona tendo menos que 25 ppm de 14 - hidroxicodeinona
CR20130455A (es) Composiciones para el tratamiento de tumores
BR0310092A (pt) Combinação de compostos orgânicos
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto
BRPI1010028A2 (pt) métodos de tratamento de encefalopatia hepática
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
BRPI0510947A (pt) tratamento de doença respiratória
UA95627C2 (ru) Аминотиазолы и их применение
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
WO2005118636A3 (en) Tgf derepressors and uses related thereto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.